NYSE:NKGN NKGen Biotech (NKGN) Stock Price, News & Analysis $0.13 -0.01 (-8.62%) As of 08/28/2025 12:37 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NKGen Biotech Stock (NYSE:NKGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NKGen Biotech alerts:Sign Up Key Stats Today's Range$0.13▼$0.1350-Day Range$0.13▼$0.3352-Week Range$0.10▼$0.96Volume851 shsAverage Volume1.58 million shsMarket Capitalization$5.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California. Read More Receive NKGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NKGN Stock News HeadlinesNKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology SummitAugust 6, 2025 | globenewswire.comNKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025July 29, 2025 | finance.yahoo.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 29 at 2:00 AM | Weiss Ratings (Ad)NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025July 28, 2025 | globenewswire.comNKGen Biotech to Present at the Alzheimer's Association International Conference 2025July 22, 2025 | globenewswire.comNKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative DiseasesJuly 21, 2025 | finance.yahoo.comNKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to JapanJuly 17, 2025 | globenewswire.comNKGen Biotech, Inc.: NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing StandardsJuly 17, 2025 | finanznachrichten.deSee More Headlines NKGN Stock Analysis - Frequently Asked Questions How have NKGN shares performed this year? NKGen Biotech's stock was trading at $0.6552 at the beginning of the year. Since then, NKGN shares have decreased by 79.8% and is now trading at $0.1325. How do I buy shares of NKGen Biotech? Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NKGen Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that NKGen Biotech investors own include Meta Platforms (META), IonQ (IONQ), Eli Lilly and Company (LLY), NVIDIA (NVDA), Viking Therapeutics (VKTX), Adaptimmune Therapeutics (ADAP) and C3.ai (AI). Company Calendar Today8/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:NKGN Previous SymbolNYSE:NKGN CIK1845459 Webnkgenbiotech.com Phone949-396-6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.94 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-479.36% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.68) per share Price / Book-0.05Miscellaneous Outstanding Shares44,948,000Free Float40,291,000Market Cap$5.96 million OptionableNot Optionable Beta1.19 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:NKGN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.